Replies to post #41 on Compugen Ltd (CGEN)

[midastouch017]

Bullishalerts.com: Daily Watch List
via COMTEX

January 30, 2007

Philadelphia, PA, Jan 30, 2007 (M2 PRESSWIRE via COMTEX News Network) --

Bullish Alerts is currently monitoring the following Stocks: Compugen Ltd. (NASDAQ: CGENFor a comprehensive report please visit www.bullishalerts.com/APIO011.htm

Compugen Ltd. (NASDAQ: CGEN) Closed Mondays trading session at (2.85) per share down 0.6% on 212,962 volume while 331 trades were placed. On Jan. 30th Compugen Ltd. announced that it has signed an agreement with Teva Pharmaceutical Industries (NASDAQ: TEVA) to collaborate on a project for the discovery of biomarkers for the detection of drug toxicity in preclinical stages of the drug development process. According to the agreement, the initial focus of the collaboration will be on biomarkers for the early detection of potential nephrotoxicity. The parties may jointly choose to expand the scope of the collaboration to include biomarkers for the detection of hepatotoxicity and/or cardiotoxicity in response to drug treatment. Under the terms of the agreement, Compugen has granted Teva a license to use the discovered markers for research and development activities while retaining commercialization rights for licensing to other companies, as well as rights for internal use.

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies.